Physician profile
Quan Wang
NPI 1043475676
$15,526.49
in general payments reported to CMS, 2019-2025
31 companies · $6,452 in 2025
The $6,452 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $394 · 2021: $880 · 2022: $1,259 · 2023: $1,846 · 2024: $3,845 · 2025: $6,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,867 · Food and Beverage: $5,087 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,867.05 |
| Food and Beverage | $5,087.26 |
| Education | $189.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,867.05 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $1,053.33 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $919.70 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $755.05 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $650.94 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $640.28 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $571.29 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $463.97 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $455.42 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $352.68 | 2021-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $352.12 | 2021-2025 | |
| Akebia Therapeutics INC | $326.23 | 2020-2025 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $324.78 | 2019-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $248.76 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $211.86 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $167.33 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $150.67 | 2021-2023 | |
| Travere Therapeutics, INC. | $145.99 | 2023-2025 | Filspari |
| Boston Scientific Corporation | $140.03 | 2023 | |
| Calliditas Therapeutics US INC. | $131.50 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $128.30 | 2022-2023 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $113.22 | 2025 | |
| Alexion Pharmaceuticals, INC. | $112.60 | 2023-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $78.09 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.27 | 2025 | Jardiance |
| Genentech USA, INC. | $37.59 | 2019 | |
| Kyowa Kirin, INC. | $23.76 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.18 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.84 | 2022 | |
| Biomerieux INC | $9.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.